» Articles » PMID: 25093707

New Technologies Provide Quantum Changes in the Scale, Speed, and Success of SELEX Methods and Aptamer Characterization

Overview
Publisher Cell Press
Date 2014 Aug 6
PMID 25093707
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Single-stranded oligonucleotide aptamers have attracted great attention in the past decade because of their diagnostic and therapeutic potential. These versatile, high affinity and specificity reagents are selected by an iterative in vitro process called SELEX, Systematic Evolution of Ligands by Exponential Enrichment. Numerous SELEX methods have been developed for aptamer selections; some that are simple and straightforward, and some that are specialized and complicated. The method of SELEX is crucial for selection of an aptamer with desired properties; however, success also depends on the starting aptamer library, the target molecule, aptamer enrichment monitoring assays, and finally, the analysis and characterization of selected aptamers. Here, we summarize key recent developments in aptamer selection methods, as well as other aspects of aptamer selection that have significant impact on the outcome. We discuss potential pitfalls and limitations in the selection process with an eye to aid researchers in the choice of a proper SELEX strategy, and we highlight areas where further developments and improvements are desired. We believe carefully designed multiplexed selection methods, when complemented with high-throughput downstream analysis and characterization assays, will yield numerous high-affinity aptamers to protein and small molecule targets, and thereby generate a vast array of reagents for probing basic biological mechanisms and implementing new diagnostic and therapeutic applications in the near future.

Citing Articles

Targeting ocular tissues with intravenously administered aptamers selected by SELEX.

Korhonen S, Stenberg K, Seemab U, Bartos P, Makiniemi K, Kjems J Mol Ther Nucleic Acids. 2024; 35(4):102352.

PMID: 39469668 PMC: 11513532. DOI: 10.1016/j.omtn.2024.102352.


Capture of RNA G-quadruplex structures using an l-RNA aptamer.

Lam S, Umar M, Zhao H, Zhao J, Kwok C RSC Chem Biol. 2024; .

PMID: 39219982 PMC: 11359968. DOI: 10.1039/d4cb00161c.


Computational Frontiers in Aptamer-Based Nanomedicine for Precision Therapeutics: A Comprehensive Review.

Kumar S, Mohan A, Sharma N, Kumar A, Girdhar M, Malik T ACS Omega. 2024; 9(25):26838-26862.

PMID: 38947800 PMC: 11209897. DOI: 10.1021/acsomega.4c02466.


Structurally reconfigurable designer RNA structures for nanomachines.

Jiao K, Hao Y, Wang F, Wang L, Fan C, Li J Biophys Rep. 2023; 7(1):21-34.

PMID: 37288082 PMC: 10240537. DOI: 10.52601/bpr.2021.200053.


Evolution of Cell-Type-Specific RNA Aptamers via Live Cell-Based SELEX.

Herrera A, Zhou J, Song M, Rossi J Methods Mol Biol. 2023; 2666:317-346.

PMID: 37166674 DOI: 10.1007/978-1-0716-3191-1_22.


References
1.
McNamara J, Kolonias D, Pastor F, Mittler R, Chen L, Giangrande P . Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest. 2007; 118(1):376-86. PMC: 2104483. DOI: 10.1172/JCI33365. View

2.
Wong I, Lohman T . A double-filter method for nitrocellulose-filter binding: application to protein-nucleic acid interactions. Proc Natl Acad Sci U S A. 1993; 90(12):5428-32. PMC: 46733. DOI: 10.1073/pnas.90.12.5428. View

3.
Jain R, DeVine T, George A, Chittur S, Baroni T, Penalva L . RIP-Chip analysis: RNA-Binding Protein Immunoprecipitation-Microarray (Chip) Profiling. Methods Mol Biol. 2010; 703:247-63. DOI: 10.1007/978-1-59745-248-9_17. View

4.
Park J, Lee S, Choi E, Kim J, Song J, Gu M . An ultra-sensitive detection of a whole virus using dual aptamers developed by immobilization-free screening. Biosens Bioelectron. 2013; 51:324-9. DOI: 10.1016/j.bios.2013.07.052. View

5.
Nitsche A, Kurth A, Dunkhorst A, Panke O, Sielaff H, Junge W . One-step selection of Vaccinia virus-binding DNA aptamers by MonoLEX. BMC Biotechnol. 2007; 7:48. PMC: 1994675. DOI: 10.1186/1472-6750-7-48. View